poisar

Stocks · News reference

JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

Aug 11, 2026, 2:50 PMBenzinga Newsdesk

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VKTX
Source
benzinga
Observed
Aug 11, 2026, 2:50 PM
Checked
Aug 11, 2026, 2:50 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 2:45 PMLee Samaha

    Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

    Viking Therapeutics has sufficient cash reserves ($502M) to fund operations through 2028, with a key near-term catalyst in Q3 2026 when phase 1 maintenance trial data for its lead drug VK2735 will be released. This data could significantly impact investor sentiment regarding the company's dual-formulation strategy (subcutaneous injection followed by oral maintenance), though it's unlikely to derail the ongoing phase 3 trials. The trial results will inform dosing decisions for upcoming extension studies.

    Read original at the-motley-fool
    VKTX
  2. Aug 6, 2026, 2:21 PMLee Samaha

    Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

    Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

    Read original at the-motley-fool
    VKTXLLYNVO
  3. Jul 30, 2026, 10:30 PMProsper Junior Bakiny

    Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

    Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics, Viking Therapeutics emerges as a potential takeover target due to its promising weight-loss drug pipeline, particularly VK2735 in phase 3 trials. The anti-obesity market is projected to reach $190 billion by 2035, making it attractive for pharmaceutical giants seeking to acquire proven candidates rather than develop from scratch. However, Viking's stock carries significant risk tied to upcoming phase 3 data readouts.

    Read original at the-motley-fool
    VRTXVKTXLLYCRNX